Gwendolyn Whitney

Gwendolyn Whitney is a seasoned executive in the biopharmaceutical industry, currently serving as President and Head of US Business at Amicus Therapeutics since March 2025. Prior to this role, Gwendolyn was the Senior Vice President and Commercial Lead at Vir Biotechnology, Inc. from September 2024 to February 2025, and held various leadership positions at Johnson & Johnson and Global Blood Therapeutics, where significant contributions included overseeing US Commercial Operations and Market Access. Gwendolyn's tenure at Gilead Sciences lasted nearly a decade, culminating as Executive Director of US Commercial Operations, where leadership encompassed a wide array of commercial disciplines. Gwendolyn's earlier career includes commercial roles at NitroMed, Takeda, and Roche, alongside a strong educational background with a Bachelor of Science in Business Administration from the University of Missouri-Columbia and an Executive MBA in Pharmaceutical Marketing and Management from Saint Joseph's University.